[144] BICYCLE THERAPEUTICS PLC SEC Filing

Rhea-AI Filing Summary

Bicycle Therapeutics plc (BCYC) filing a Form 144 notifies the SEC of a proposed sale of 486 shares of common stock with an aggregate market value of $3,447.00, scheduled for 10/02/2025 on Nasdaq. The filing shows those shares were acquired the same day as restricted stock units (RSUs) and paid as equity compensation, with an acquisition quantity of 750 RSU units dated 10/02/2025. The filer also reported a prior sale of 206 shares on 07/02/2025 for gross proceeds of $1,461.00. The company's outstanding share count listed in the form is 49,868,567, which places the proposed sale at a de minimis fraction of total shares outstanding.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	486	3447.00	49868567	10/02/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	10/02/2025	Restricted Stock Units	Issuer			750	10/02/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Alethia Young Blocks A & B Portway Building Cambridge X0 CB21 6GS	Common Stock	07/02/2025	206	1461.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does BCYC's Form 144 report?

The Form 144 reports a proposed sale of 486 shares of Bicycle Therapeutics common stock with an aggregate market value of $3,447.00, planned for 10/02/2025 on Nasdaq.

Who acquired the securities and how were they paid?

The filing shows the securities were acquired as Restricted Stock Units from the issuer on 10/02/2025 and the payment type is listed as Equity Compensation.

Has the filer recently sold other BCYC shares?

Yes. The filer sold 206 shares on 07/02/2025 for gross proceeds of $1,461.00 as disclosed in the form.

How large is the proposed sale relative to outstanding shares?

The form lists 49,868,567 shares outstanding; the proposed 486-share sale represents a very small fraction of total outstanding shares.

On which exchange will the shares be sold?

The filing specifies the sale is expected to occur on Nasdaq.